


**Claim Amendments**

1(previously presented). A compound of Formula (I)



wherein

A is N;

R<sup>0</sup> is an optionally substituted aryl or an optionally substituted heteroaryl;

R<sup>1</sup> is an optionally substituted aryl or an optionally substituted heteroaryl;

R<sup>3</sup> is hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with one or more substituents, or (C<sub>1</sub>-C<sub>4</sub>)alkoxy; and

R<sup>4</sup> is a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>9</sub>)alkyl, aryl, heteroaryl, aryl(C<sub>1</sub>-C<sub>5</sub>)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C<sub>1</sub>-C<sub>3</sub>)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

2-9 (cancelled).

10(previously presented). The compound of Claim 1 wherein

R<sup>3</sup> is hydrogen or (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with one or more fluorines; and

R<sup>4</sup> is a chemical moiety selected from (C<sub>1</sub>-C<sub>9</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>5</sub>)alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring, or 3- to 6-membered partially or fully saturated heterocyclic ring, where the chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt.

11(original). The compound of Claim 10 wherein

R<sup>3</sup> is hydrogen or methyl;

R<sup>4</sup> is fluoro-substituted (C<sub>1</sub>-C<sub>5</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>5</sub>)alkyl, cyclopentyl, cyclohexyl, pyranyl, furanyl, pyrrolidinyl, piperidinyl, or morpholinyl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt.

12(currently amended). The compound of Claim 9, 10, or 11 wherein R<sup>0</sup> and R<sup>1</sup> are each independently a chemical moiety selected from phenyl or pyridyl, where said chemical moiety is substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

13(currently amended). The compound of Claim 9, 10, or 11 wherein R<sup>0</sup> and R<sup>1</sup> are each independently a phenyl or pyridyl, where said phenyl and said pyridyl are each substituted with 1 to 3 substituents independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, and cyano;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

14(original). The compound of Claim 13 selected from the group consisting of

2-(2-chlorophenyl)-6-(2,2,2-trifluoroethyl)-3-(6-(trifluoromethyl)pyridin-3-yl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

3-(5-butylpyridin-2-yl)-2-(2-chlorophenyl)-6-(2,2,2-trifluoroethyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

3-(4-chlorophenyl)-2-(3,5-dichloropyridin-2-yl)-6-(2,2,2-trifluoroethyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-3-(6-chloropyridazin-3-yl)-6-(2,2,2-trifluoroethyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-3-(6-chloropyridin-3-yl)-6-(2,2-difluoropropyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; and

3-(4-chlorophenyl)-2-(3-chloropyridin-2-yl)-6-(2,2,2-trifluoroethyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

a pharmaceutically acceptable solvate or hydrate of said compound.

15(original). The compound of Claim 13 wherein  $R^0$  and  $R^1$  are each independently a phenyl substituted with 1 to 2 substituents independently selected from the group consisting of chloro, fluoro,  $(C_1-C_4)$ alkoxy,  $(C_1-C_4)$ alkyl, fluoro-substituted  $(C_1-C_4)$ alkyl, and cyano;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

16(original). The compound of Claim 15 wherein  $R^0$  is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl; and  $R^1$  is 4-chlorophenyl, 4-cyanophenyl, 4-trifluoromethylphenyl, or 4-fluorophenyl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

17(original). The compound of Claim 16 selected from the group consisting of

3-(4-chlorophenyl)-2-(2-ethylphenyl)-6-(2,2,2-trifluoroethyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-6-(2,2,2-trifluoroethyl)-3-(4-propoxyphenyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

3-(4-butylphenyl)-2-(2-chlorophenyl)-6-(2,2,2-trifluoroethyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-6-(2,2-difluoropropyl)-3-(4-methoxyphenyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

3-(4-bromophenyl)-2-(2-chlorophenyl)-6-(2,2-difluoropropyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-3-(4-chlorophenyl)-5-ethyl-6-(2,2,2-trifluoroethyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-bromophenyl)-3-(4-chlorophenyl)-6-(2,2,2-trifluoroethyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(3-(4-chlorophenyl)-6-(2,2,2-trifluoroethyl)-6,7-dihydro-5-methyl-7-oxopyrazolo[4,3-d]pyrimidin-2-yl)benzonitrile;

2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-(2,2-difluoropropyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

3-(4-bromophenyl)-2-(2-chlorophenyl)-6-(2,2,2-trifluoroethyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-3-(4-ethylphenyl)-6-(2,2,2-trifluoroethyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(3-(4-chlorophenyl)-6-(2,2-difluoropropyl)-6,7-dihydro-5-methyl-7-oxopyrazolo[4,3-d]pyrimidin-2-yl)benzonitrile;

2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-(2,2,2-trifluoroethyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-bromophenyl)-3-(4-chlorophenyl)-6-(2,2-difluoropropyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-6-(2,2,2-trifluoroethyl)-3-(4-(trifluoromethyl)phenyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-(2,2-difluoropropyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; and

2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-(2,2,2-trifluoroethyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

a pharmaceutically acceptable solvate or hydrate of said compound.

18(original). The compound of Claim 17 selected from the group consisting of

2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-(2,2,2-trifluoroethyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-bromophenyl)-3-(4-chlorophenyl)-6-(2,2-difluoropropyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-6-(2,2,2-trifluoroethyl)-3-(4-(trifluoromethyl)phenyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-(2,2-difluoropropyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one; and

2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-(2,2,2-trifluoroethyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

a pharmaceutically acceptable solvate or hydrate of said compound.


19(original). The compound of Claim 18 which is 2-(2-chlorophenyl)-3-(4-chlorophenyl)-6-(2,2,2-trifluoroethyl)-5-methyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

a pharmaceutically acceptable solvate or hydrate of said compound.

20(original). The compound of Claim 18 which is 2-(2-chlorophenyl)-6-(2,2,2-trifluoroethyl)-3-(4-(trifluoromethyl)phenyl)-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;

a pharmaceutically acceptable solvate or hydrate of said compound.

21(previously presented). A compound of Formula (II)



wherein

A is N;

$R^{0a}$ ,  $R^{0b}$ ,  $R^{1a}$ , and  $R^{1b}$  are each independently halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, or cyano;

n and m are each independently 0, 1 or 2;

$R^3$  is hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with one or more substituents, or (C<sub>1</sub>-C<sub>4</sub>)alkoxy; and

$R^4$  is a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>9</sub>)alkyl, aryl, heteroaryl, aryl(C<sub>1</sub>-C<sub>5</sub>)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C<sub>1</sub>-C<sub>3</sub>)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

22-23(cancelled).

24(original). The compound of Claim 21 wherein

A is nitrogen;

$R^3$  is hydrogen or (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with one or more fluorines; and

$R^4$  is a chemical moiety selected from (C<sub>1</sub>-C<sub>9</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>5</sub>)alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring, or 3- to 6-membered partially or fully saturated heterocyclic ring, where the chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

25(original). The compound of Claim 24 wherein

$R^3$  is hydrogen or methyl;

$R^4$  is fluoro-substituted (C<sub>1</sub>-C<sub>5</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>5</sub>)alkyl, cyclopentyl, cyclohexyl, pyranlyl, furanyl, pyrrolidinyl, piperidinyl, or morpholinyl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of the compound or the salt.

26(original). A pharmaceutical composition comprising (1) a compound of Claim 1, or a solvate or hydrate of said compound; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

27-44 (cancelled).